E061 – Pharmacogenomics and drug discovery (GenDeM)

Objectives

​The main objective is the analysis of the genetic variability that influences the individual response to drug treatments. The purpose of the group is to advance knowledge in order to discover biomarkers linked both to the prevention of adverse reactions and to the optimization of the therapeutic effectiveness of existing drugs by identifying new therapeutic targets and pharmacological approaches. In this sense, the group particularly prioritizes drugs used in the treatment of prevalent diseases that are difficult to manage therapeutically and/or high cost for the National Health System, ranging from psychiatric agents (including the use of opioids in the context of addiction) to cardiovascular and oncological agents. The main lines of research of the group have a highly translational approach and are oriented towards the direct application of the results to clinical practice, with the aim of enriching and perfecting, through Personalized Medicine, the current procedures, betting on analytical quality.

Lines of research

-Search for biomarkers in Pharmacogenomics

-Association of study variables with clinical characteristics of the patients

-Prevention, prediction and quality in Pharmacogenetics

-Identification and validation of new therapeutic targets and pharmacological approaches

-Improvement of molecular analysis methods and strategies in diagnosis in Pharmacogenetics

Mejora de la calidad clínica asistencial y la investigación traslacional en Farmacogenética
Código del proyecto: PI25/01349
Entidad financiadora: Instituto de Salud Carlos III
Duración: 3 años
Cuantía: 254.605€
Investigador/a principal:

Intervenciones Clínico-Farmacogeneticas en población infanto-juvenil [Ingenia]
Código del proyecto: PMP21/00065
Entidad financiadora: Instituto de Salud Carlos III
Duración: 3 años
Cuantía: 380.000 €
Investigador/a principal:

Elaboración de un protocolo de medicina personalizada para la administración de metadona basada en perfiles farmacogenéticos
Código del proyecto: PI22/01166
Entidad financiadora: Instituto de Salud Carlos III
Duración: 3 años
Cuantía: 66.550€
Investigador/a principal:

Evaluación de una propuesta de Implementación de la Farmacogenética en el Sistema Nacional de Salud para Salud Mental y Cardiovascular
Investigador/a principal:

Evaluación de una propuesta de Implementación de la Farmacogenética en el Sistema Nacional de Salud para Salud Mental y Cardiovascular [BioFRAM22]
Código del proyecto: PMP22/00056
Entidad financiadora: Instituto de Salud Carlos III
Duración: 3 años
Cuantía: 380.000€
Investigador/a principal:

• Sheila Recarey-Rama, Sabela Conde-Pumpido Zubizarreta, Carla Brenlla, Eva Gerpe-Rieiro, Almudena Gil-Rodriguez, María Tubío-Fungueiriño, Marta Pozo-Rodríguez, Angel Carracedo, Olalla Maroñas, Montse Fernández-Prieto. Exploring the sensory profile and pharmacogenetic biomarkers in child and youth ADHD patients undergoing methylphenidate (MPH) treatment: a systematic review conducted in European studies. J Psychiatr Res. 2025. https://doi.org/10.1016/j.jpsychires.2025.09.002

• Almudena Gil-Rodriguez, Sheila Recarey-Rama, Ana Fernández Montes, Ana Rodríguez-Viyuela, Francisco Barros, Angel Carracedo, Olalla Maroñas. A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines. Int J Mol Sci. 2025. https://doi.org/10.3390/ijms26178136

• Sheila Recarey-Rama, Jesús Gómez-Trigo, Almudena Gil-Rodriguez, Eduardo Dominguez, Inés Sánchez-Martínez, Ángela Riveiro-Recimil, Alba Barral-Raña, Jose de Leon, Ana Rodriguez-Viyuela, Manuel Arrojo, Angel Carracedo and Olalla Maroñas. The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review. Pharmaceuticals. 2025. https://doi.org/10.3390/ph18050623

• Almudena Gil-Rodriguez, Sheila Recarey-Rama, Ana Rodríguez-Viyuela, Raquel Cruz, Francisco Barros, Angel Carracedo, Olalla Maroñas. Differences in DPYD Population Frequencies Observed in Galicians Compared to Europeans and Spanish from PhotoDPYD Study. Pharmaceuticals (Basel). 2025. https://doi.org/10.3390/ph18050623

• Almudena Gil-Rodríguez, Sheila Recarey-Rama, Ana Rodríguez-Viyuela, Francisco Barros, Angel Carracedo, Olalla Maroñas. Balance of care activity after EMA recommendation for DPYD gene testing in Galicia. Front Pharmacol. 2025. https://doi.org/10.3389/fphar.2025.1523536

• Alexandre Serra-Llovich, Natalia Cullell, Olalla Maroñas, María José Herrero, Raquel Cruz, Berta Almoguera, Carmen Ayuso, Rosario Lopez-Rodriguez, Elena Dominguez-Garrido, Rocio Ortiz-Lopez, María Barreda-Sanchez, Marta Corton, David Dalmau, Esther Calbo, Lucia Boix, Beatriz Dietl, Anna San Gil, Almudena Gil-Rodriguez, Encarna Guillen-Navarro, Esther Mancebo, Pablo Minguez, Estela Paz-Artal, Sheila Recarey, Luis Sendra, Enrique G. Zucchet, Miguel Lopez de Heredia, Carlos Flores, José A. Riancho, Augusto Rojas, Pablo Lapunzina , Ángel Carracedo, Maria J Arranz, SCOURGE COHORT GROUP. Pharmacogenomic study of SARS-CoV-2 treatments. Biomedicines. 2025. https://doi.org/10.3390/biomedicines13030553

• Hélène Verdoux, Robert A Bittner, Alkomiet Hasan, Mishal Qubad, Elias Wagner, Alexis Lepetit, Manuel Arrojo-Romero, Christian Bachmann, Marieke Beex-Oosterhuis, Jan Bogers, Andreja Celofiga, Dan Cohen, Domenico DE Berardis, Marc DE Hert, Carlos DE Las Cuevas, Bjørn H Ebdrup, Konstantinos N Fountoulakis, Daniel Guinart, Dolores Keating, Miloslav Kopeček, John Lally, Judit Lazáry, Jurjen J Luykx, Olalla Maronas Amigo, Espen Molden, Jimmi Nielsen, Brian O’Donoghue, Pierre Oswald, Flavian S Radulescu, Christopher Rohde, Marina Sagud, Emilio J Sanz, Ivona Šimunović Filipčić, Iris E Sommer, Heidi Taipale, Jari Tiihonen, Heli Tuppurainen, Selene Veerman, Alina Wilkowska, Edoardo Spina, Peter Schulte. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force. Eur Psychiatry. 2025. https://doi.org/10.1192/j.eurpsy.2024.1816

• Francisco José Toja-Camba, María Vidal-Millares, María José Durán-Maseda, Gonzalo Hermelo-Vidal, Ángel Carracedo, Olalla Maroñas, Luis Ramudo-Cela, Irene Zarra-Ferro, Anxo Fernández-Ferreiro, Cristina Mondelo-García. Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrations. Sci Rep. 2025. https://doi.org/10.1038/s41598-024-84192-8